# ASCENT-04 (NCT05382286)

> Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05382286
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Gilead Sciences
- Conditions: Triple Negative Breast Cancer; PD-L1 Positive
- Interventions: Sacituzumab Govitecan-hziy; Pembrolizumab; Paclitaxel; nab-Paclitaxel; Gemcitabine; Carboplatin
- Enrollment: 443
- Primary outcome: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

## Commentary we found

- X threads: 134
- YouTube: 104
- Podcasts: 75
- X videos: 12

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ascent-04-nct05382286

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05382286", "email": "<work email>"}; the inbox owner confirms by the emailed link.